For a study, researchers sought to evaluate the effectiveness of the Sanyrene liquid dressing (Urgo Medical) in shielding cancer patients from radiation dermatitis (RD) following radiotherapy.
For publications published between the beginning and January 2021, they searched the databases of the China National Knowledge Infrastructure, SinoMed, WanFang Data, PubMed, Web of Science, EMBASE, and the Cochrane Library. The initial search yielded 146 studies. Nineteen papers satisfied the inclusion criteria after duplicates were eliminated, exclusion criteria were used, and titles and abstracts were scrutinized. To gather information from appropriate research, a uniform form was developed. Two reviewers independently read the literature, collected the data, and evaluated the included studies’ bias risk.
The effectiveness of Sanyrene liquid dressing in avoiding RD in cancer patients following radiation was evaluated in a total of 19 trials, including 1,508 patients, according to the authors. The results showed that Sanyrene lowered the overall incidence of RD (odds ratio [OR], 5.00; 95% CI, 2.77-9.03; P<.00001), as well as the incidence of RD grades 2 and higher (OR, 0.55; 95% CI, 0.36-0.85; P =.007), grade 3 (OR, 0.22; 95% CI, 0.09-0.57; P =.002), and grade 4 (OR, 0.32; 95% CI, 0.13–0.78; P=.01). Sanyrene liquid dressing also delays the emergence of RD (mean difference, 3.69; 95% CI, 3.03-4.36; P< .00001) and increases the cure rate when compared to controls (OR, 8.18; 95% CI, 4.03-16.60; P< .00001).
Both the overall incidence of RD and the incidence of RD above grade 2 can be reduced by sanyrene liquid dressing. Additionally, it increases the cure rate and postpones the onset of RD. Sanyrene is a better option for preventing RD following radiotherapy. More high-quality trials are required in order to support these findings because the findings were rated as having moderate- to low-quality evidence.